Cargando…

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma

BACKGROUND: Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histiocytosis and Erdheim‐Chester disease have been well described, other less common and often aggressive tumors in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Massoth, Lucas R., Hung, Yin P., Ferry, Judith A., Hasserjian, Robert P., Nardi, Valentina, Nielsen, G. Petur, Sadigh, Sam, Venkataraman, Vinayak, Selig, Martin, Friedmann, Alison M., Samore, Wesley, Killian, Jonathan Keith, Milante, Riza, Giessinger, Joseph, Foley‐Peres, Kathleen, Marcus, Chelsea, Severson, Eric, Duncan, Daniel, Sivakumar, Smruthy, Ross, Jeffrey S., Desphande, Vikram, Ramkissoon, Shakti H., Vergilio, Jo‐Anne, Louissaint, Abner, Zukerberg, Lawrence R., Williams, Erik A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265357/
https://www.ncbi.nlm.nih.gov/pubmed/33904632
http://dx.doi.org/10.1002/onco.13801
_version_ 1783719749792825344
author Massoth, Lucas R.
Hung, Yin P.
Ferry, Judith A.
Hasserjian, Robert P.
Nardi, Valentina
Nielsen, G. Petur
Sadigh, Sam
Venkataraman, Vinayak
Selig, Martin
Friedmann, Alison M.
Samore, Wesley
Killian, Jonathan Keith
Milante, Riza
Giessinger, Joseph
Foley‐Peres, Kathleen
Marcus, Chelsea
Severson, Eric
Duncan, Daniel
Sivakumar, Smruthy
Ross, Jeffrey S.
Desphande, Vikram
Ramkissoon, Shakti H.
Vergilio, Jo‐Anne
Louissaint, Abner
Zukerberg, Lawrence R.
Williams, Erik A.
author_facet Massoth, Lucas R.
Hung, Yin P.
Ferry, Judith A.
Hasserjian, Robert P.
Nardi, Valentina
Nielsen, G. Petur
Sadigh, Sam
Venkataraman, Vinayak
Selig, Martin
Friedmann, Alison M.
Samore, Wesley
Killian, Jonathan Keith
Milante, Riza
Giessinger, Joseph
Foley‐Peres, Kathleen
Marcus, Chelsea
Severson, Eric
Duncan, Daniel
Sivakumar, Smruthy
Ross, Jeffrey S.
Desphande, Vikram
Ramkissoon, Shakti H.
Vergilio, Jo‐Anne
Louissaint, Abner
Zukerberg, Lawrence R.
Williams, Erik A.
author_sort Massoth, Lucas R.
collection PubMed
description BACKGROUND: Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histiocytosis and Erdheim‐Chester disease have been well described, other less common and often aggressive tumors in this broad category remain poorly characterized, and comparison studies across the World Health Organization diagnostic categories are lacking. METHODS: Tumor samples from a total of 102 patient cases within four major subtypes of malignant histiocytic and dendritic cell neoplasms, including 44 follicular dendritic cell sarcomas (FDCSs), 41 histiocytic sarcomas (HSs), 7 interdigitating dendritic cell sarcomas (IDCSs), and 10 Langerhans cell sarcomas (LCSs), underwent hybridization capture with analysis of up to 406 cancer‐related genes. RESULTS: Among the entire cohort of 102 patients, CDKN2A mutations were most frequent across subtypes and made up 32% of cases, followed by TP53 mutations (22%). Mitogen‐activated protein kinase (MAPK) pathway mutations were present and enriched among the malignant histiocytosis (M) group (HS, IDCS, and LCS) but absent in FDCS (72% vs. 0%; p < .0001). In contrast, NF‐κB pathway mutations were frequent in FDCSs but rare in M group histiocytoses (61% vs. 12%; p < .0001). Tumor mutational burden was significantly higher in M group histiocytoses as compared with FDCSs (median 4.0/Mb vs. 2.4/Mb; p = .012). We also describe a pediatric patient with recurrent secondary histiocytic sarcoma treated with targeted therapy and interrogated by molecular analysis to identify mechanisms of therapeutic resistance. CONCLUSION: A total of 42 patient tumors (41%) harbored pathogenic mutations that were potentially targetable by approved and/or investigative therapies. Our findings highlight the potential value of molecular testing to enable precise tumor classification, identify candidate oncogenic drivers, and define personalized therapeutic options for patients with these aggressive tumors. IMPLICATIONS FOR PRACTICE: This study presents comprehensive genomic profiling results on 102 patient cases within four major subtypes of malignant histiocytic and dendritic cell neoplasms, including 44 follicular dendritic cell sarcomas (FDCSs), 41 histiocytic sarcomas (HSs), 7 interdigitating dendritic cell sarcomas (IDCSs), and 10 Langerhans cell sarcomas (LCSs). MAPK pathway mutations were present and enriched among the malignant histiocytosis (M) group (HS, IDCS, and LCS) but absent in FDCSs. In contrast, NF‐κB pathway mutations were frequent in FDCSs but rare in M group histiocytosis. A total of 42 patient tumors (41%) harbored pathogenic mutations that were potentially targetable by approved and/or investigative therapies.
format Online
Article
Text
id pubmed-8265357
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-82653572021-07-13 Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma Massoth, Lucas R. Hung, Yin P. Ferry, Judith A. Hasserjian, Robert P. Nardi, Valentina Nielsen, G. Petur Sadigh, Sam Venkataraman, Vinayak Selig, Martin Friedmann, Alison M. Samore, Wesley Killian, Jonathan Keith Milante, Riza Giessinger, Joseph Foley‐Peres, Kathleen Marcus, Chelsea Severson, Eric Duncan, Daniel Sivakumar, Smruthy Ross, Jeffrey S. Desphande, Vikram Ramkissoon, Shakti H. Vergilio, Jo‐Anne Louissaint, Abner Zukerberg, Lawrence R. Williams, Erik A. Oncologist Sarcomas BACKGROUND: Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histiocytosis and Erdheim‐Chester disease have been well described, other less common and often aggressive tumors in this broad category remain poorly characterized, and comparison studies across the World Health Organization diagnostic categories are lacking. METHODS: Tumor samples from a total of 102 patient cases within four major subtypes of malignant histiocytic and dendritic cell neoplasms, including 44 follicular dendritic cell sarcomas (FDCSs), 41 histiocytic sarcomas (HSs), 7 interdigitating dendritic cell sarcomas (IDCSs), and 10 Langerhans cell sarcomas (LCSs), underwent hybridization capture with analysis of up to 406 cancer‐related genes. RESULTS: Among the entire cohort of 102 patients, CDKN2A mutations were most frequent across subtypes and made up 32% of cases, followed by TP53 mutations (22%). Mitogen‐activated protein kinase (MAPK) pathway mutations were present and enriched among the malignant histiocytosis (M) group (HS, IDCS, and LCS) but absent in FDCS (72% vs. 0%; p < .0001). In contrast, NF‐κB pathway mutations were frequent in FDCSs but rare in M group histiocytoses (61% vs. 12%; p < .0001). Tumor mutational burden was significantly higher in M group histiocytoses as compared with FDCSs (median 4.0/Mb vs. 2.4/Mb; p = .012). We also describe a pediatric patient with recurrent secondary histiocytic sarcoma treated with targeted therapy and interrogated by molecular analysis to identify mechanisms of therapeutic resistance. CONCLUSION: A total of 42 patient tumors (41%) harbored pathogenic mutations that were potentially targetable by approved and/or investigative therapies. Our findings highlight the potential value of molecular testing to enable precise tumor classification, identify candidate oncogenic drivers, and define personalized therapeutic options for patients with these aggressive tumors. IMPLICATIONS FOR PRACTICE: This study presents comprehensive genomic profiling results on 102 patient cases within four major subtypes of malignant histiocytic and dendritic cell neoplasms, including 44 follicular dendritic cell sarcomas (FDCSs), 41 histiocytic sarcomas (HSs), 7 interdigitating dendritic cell sarcomas (IDCSs), and 10 Langerhans cell sarcomas (LCSs). MAPK pathway mutations were present and enriched among the malignant histiocytosis (M) group (HS, IDCS, and LCS) but absent in FDCSs. In contrast, NF‐κB pathway mutations were frequent in FDCSs but rare in M group histiocytosis. A total of 42 patient tumors (41%) harbored pathogenic mutations that were potentially targetable by approved and/or investigative therapies. John Wiley & Sons, Inc. 2021-05-06 2021-07 /pmc/articles/PMC8265357/ /pubmed/33904632 http://dx.doi.org/10.1002/onco.13801 Text en © 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Sarcomas
Massoth, Lucas R.
Hung, Yin P.
Ferry, Judith A.
Hasserjian, Robert P.
Nardi, Valentina
Nielsen, G. Petur
Sadigh, Sam
Venkataraman, Vinayak
Selig, Martin
Friedmann, Alison M.
Samore, Wesley
Killian, Jonathan Keith
Milante, Riza
Giessinger, Joseph
Foley‐Peres, Kathleen
Marcus, Chelsea
Severson, Eric
Duncan, Daniel
Sivakumar, Smruthy
Ross, Jeffrey S.
Desphande, Vikram
Ramkissoon, Shakti H.
Vergilio, Jo‐Anne
Louissaint, Abner
Zukerberg, Lawrence R.
Williams, Erik A.
Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
title Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
title_full Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
title_fullStr Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
title_full_unstemmed Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
title_short Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
title_sort histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma
topic Sarcomas
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265357/
https://www.ncbi.nlm.nih.gov/pubmed/33904632
http://dx.doi.org/10.1002/onco.13801
work_keys_str_mv AT massothlucasr histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT hungyinp histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT ferryjuditha histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT hasserjianrobertp histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT nardivalentina histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT nielsengpetur histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT sadighsam histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT venkataramanvinayak histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT seligmartin histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT friedmannalisonm histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT samorewesley histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT killianjonathankeith histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT milanteriza histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT giessingerjoseph histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT foleypereskathleen histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT marcuschelsea histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT seversoneric histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT duncandaniel histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT sivakumarsmruthy histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT rossjeffreys histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT desphandevikram histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT ramkissoonshaktih histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT vergiliojoanne histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT louissaintabner histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT zukerberglawrencer histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma
AT williamserika histiocyticanddendriticcellsarcomasofhematopoieticoriginsharetargetablegenomicalterationsdistinctfromfolliculardendriticcellsarcoma